Dec-18 -

Genito-Urinary Group

EORTC 30073 – Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.

EORTC study compared two treatment regimens in patients with synchronous metastatic renal cell carcinoma. It found that deferring cytoreductive nephrectomy (CN) to after chemotherapy treatment with suntinib, does not improve progression free survival, although overall survival was slightly higher in patients with primary metastatic renal cell carcinoma (mRCC). However, pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN.

READ MORE

Go to Top